Biomednewsbreaks Heartbeam Inc.'S (NASDAQ: BEAT) First-Of-Its-Kind Cable-Free ECG Offers Multi-Angle Signal Capture

(MENAFN- Investor Brand Network) As clinicians increasingly recognize the value of accurate at-home electrocardiogram (“ECG”) capture, HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation. The company's FDA-cleared HeartBeam System is the first cable-free ECG device that captures the heart's signals from three distinct directions and is designed to be a groundbreaking solution for at-home detection and monitoring of arrhythmias.“HeartBeam's proprietary system allows for high-fidelity measurements without the complexity of conventional equipment. Unlike standard devices that capture electrical signals from limited perspectives, HeartBeam's patented approach records from three distinct angles, enabling a more complete view of the heart's electrical activity. This expanded data capture is intended to improve diagnostic precision, particularly for arrhythmias that may be missed with traditional methods. Additionally, the patient can always have the device with them and take a recording at the time of symptom onset, potentially reducing any delays in care.”

To view the full article, visit

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit .

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN22092025000224011066ID1110095148